Skyrizi 360 MG/2.4 ML on-body 2.4ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9FN4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,467
Award facts
- Contract value 100% obligated
- $12,467.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $12,467.00 by the Defense Logistics Agency on December 11, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body applicators. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award through open procurement. The award is set to conclude on January 5, 2026, with the place of performance located at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026.
This contract supports the Defense Logistics Agency's Medical Supply Chain operations, enabling the delivery of specialized pharmaceutical products to military healthcare systems. SKYRIZI, a biologic treatment for immunological conditions, represents the type of specialty medication that AmerisourceBergen supplies across its extensive federal contract portfolio. The company's demonstrated capability to fulfill federal medical procurement requirements through competitive awards, combined with its role as a prime vendor for DLA Troop Support, positions it as a critical supplier for Department of Defense healthcare initiatives. The DLA's ongoing modernization efforts, including planned Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, reflect the agency's reliance on established vendors like AmerisourceBergen to sustain comprehensive pharmaceutical support for military personnel worldwide.
Quick answers
Who was awarded contract SPE2DR26F9FN4?
SPE2DR26F9FN4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26F9FN4 worth?
The government has obligated $12,467 on SPE2DR26F9FN4.
Is contract SPE2DR26F9FN4 an order under another contract?
Yes. SPE2DR26F9FN4 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9FN4 competed?
The extent of competition for SPE2DR26F9FN4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award